Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104811 | 0.76 | APP (0.32) | — | |
| SCHEMBL1338455 | 0.76 | HRH3 (0.35) | HRH3LOXL2CYP3A4TSHR | |
| SCHEMBL3033222 | 0.75 | FFAR1 (0.37) | FFAR1TSHR | |
| SCHEMBL1516489 | 0.74 | TSHR (0.43) | FFAR1TSHR | |
| SCHEMBL1802180 | 0.74 | CA1 (0.43) | CYP2A6LOXL2FFAR1CYP3A4TSHR | |
| SCHEMBL23091413 | 0.74 | IDO1 (0.46) | CYP2A6LOXL2FFAR1CYP3A4TSHR | |
| SCHEMBL720296 | 0.74 | HDAC8 (0.40) | HRH3CYP2A6LOXL2FFAR1 | |
| SCHEMBL6249906 | 0.74 | TSHR (0.43) | CYP2A6LOXL2FFAR1CYP3A4TSHR | |
| SCHEMBL10270726 | 0.74 | LOXL2 (0.58) | CYP2A6LOXL2TSHR | |
| SCHEMBL225425 | 0.74 | CYP2A6 (0.58) | CYP2A6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101856502-A | Radiolabeling insulin | HAMMERSMITH IMANET LTD | 2010-10-13 | — | — | CN | disclosed |
| US-20080213174-A1 | Radiolabelled Insulin | GLASER MATTHIAS EBERHARD | 2008-09-04 | — | — | US | disclosed |
| CN-101052423-A | Radiolabelled insulin | AMERSHAM HEALTH AS (GB) | 2007-10-10 | — | — | CN | disclosed |
| EP-1789098-A2 | RADIOLABELLED INSULIN | Hammersmith Imanet, Ltd (GB) | 2007-05-30 | — | — | EP | disclosed |
| EP-1722827-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | Schering AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| CN-1758925-A | Radiofluorination method of bioactive carrier | AMERSHAM HEALTH AS (NO) | 2006-04-12 | — | — | CN | disclosed |
| WO-2006030197-A2 | RADIOLABELLED INSULIN | HAMMERSMITH IMANET LTD (GB) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005089815-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | SCHERING AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-5280015-A | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-18 | — | — | US | disclosed |
| US-5098996-A | Fluorination of compounds for use in diagnosis of nuclear medicine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213174-A1 | Radiolabelled Insulin | INSR, GPR119, IAPP | HRH3 93/4885CYP2A6 2079/4885LOXL2 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.